# Mablink Bioscience

Source: https://onco.cc/companies/mablink-bioscience/  
OnCo record `mablink-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mablink Bioscience, from Lyon, invented PSARlink, a water-soluble polysarcosine linker that hides the greasy cell-killing payload so an antibody can carry a higher load of drug molecules and still stay stable in the blood. Eli Lilly bought the company in 2023, before any of its medicines had reached patients.

## Summary

Mablink Bioscience was a preclinical Lyon-based biotech whose PSARlink platform uses a hydrophilic polysarcosine linker arm to mask hydrophobic cytotoxic payloads, enabling homogeneous, plasma-stable antibody-drug conjugates with high drug-to-antibody ratios while preserving pharmacokinetics and tolerability; PSARlink ADCs showed an improved therapeutic index in animal models. The company was funded by a 2021 seed round led by Elaia Partners with UI Investissement and Relyens Innovation Santé, and a July 2022 Series A led by Sofinnova Partners and Mérieux Equity Partners. On 18 October 2023 Mablink announced an agreement to be acquired by Eli Lilly, subject to French Ministry of the Economy approval; terms were not disclosed. The company domain now redirects to lilly.com.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Lyon
- Type: biotech
- Website: https://www.lilly.com/

## Notes

- mablink.com redirects to lilly.com, recorded as the website. Series A amount (reported elsewhere as EUR 31 million) not stated in the fetched source and omitted. GlobeNewswire original could not be fetched.

## Sources

- Official website: https://www.lilly.com/
- Acquisition announcement (BioSpace copy): https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/), [Sofinnova Partners](https://onco.cc/companies/sofinnova-partners/)

---
JSON: https://onco.cc/api/v1/entities/mablink-bioscience.json